scholarly journals Artificial Oxygen Carriers

2017 ◽  
Vol 41 (4) ◽  
pp. 311-311 ◽  
Author(s):  
Paul S. Malchesky
2021 ◽  
Vol 28 ◽  
Author(s):  
Hiromi Sakai ◽  
Naoko Kobayashi ◽  
Tomoko Kure ◽  
Chie Okuda

: Clinical situations arise in which blood for transfusion becomes scarce or unavailable. Considerable demand for a transfusion alternative persists because of various difficulties posed by blood donation and transfusion systems. Hemoglobin-vesicles (HbV) are artificial oxygen carriers being developed for use as a transfusion alternative. Just as biomembranes of red blood cells (RBCs) do, phospholipid vesicles (liposomes) for Hb encapsulation can protect the human body from toxic effects of molecular Hb. The main HbV component, Hb, is obtained from discarded human donated blood. Therefore, HbV can be categorized as a biologic agent targeting oxygen for peripheral tissues. The purification procedure strictly eliminates the possibility of viral contamination. It also removes all concomitant unstable enzymes present in RBC for utmost safety from infection. The deoxygenated HbVs, which are storable for over years at ambient temperature, can function as an alternative to blood transfusion for resuscitation from hemorrhagic shock and O2 therapeutics. Moreover, a recent study clarified beneficial effects for anti-oxidation and anti-inflammation by carbon monoxide (CO)-bound HbVs. Autoxidation of HbV (HbO2 → metHb + O2-.) is unavoidable after intravenous administration. Co-injection of methylene blue can extract the intraerythrocytic glycolytic electron energy effectively and reduce metHb. Other phenothiazine dyes can also function as electron mediators to improve the functional life span of HbV. This review paper summarizes recent progress of the research and development of HbV, aimed at clinical applications.


2003 ◽  
pp. 397-405
Author(s):  
M.R. Davey ◽  
P. Anthony ◽  
J.B. Power ◽  
K.C. Lowe

2018 ◽  
Vol 2 (2) ◽  
pp. 90-94 ◽  
Author(s):  
Stéphanie Devineau ◽  
Laurent Kiger ◽  
Frédéric Galacteros ◽  
Véronique Baudin-Creuza ◽  
Michael Marden ◽  
...  

Key Points Silica nanoparticles act as an effector for human native and sickle cell hemoglobin while preserving their tetrameric structure. Manipulating hemoglobin oxygenation using nanoparticles opens the way for the rational design of hemoglobin-based oxygen carriers.


2019 ◽  
Vol 87 ◽  
pp. S48-S58 ◽  
Author(s):  
Christopher Bialas ◽  
Christopher Moser ◽  
Carrie A. Sims

2009 ◽  
Vol 33 (2) ◽  
pp. 139-145 ◽  
Author(s):  
Hiromi Sakai ◽  
Keitaro Sou ◽  
Hirohisa Horinouchi ◽  
Koichi Kobayashi ◽  
Eishun Tsuchida

2004 ◽  
Vol 65 (10) ◽  
pp. 582-588 ◽  
Author(s):  
Colin F Mackenzie ◽  
Cyndi Bucci

Sign in / Sign up

Export Citation Format

Share Document